---
title: "Valvular Heart Surgery"
order: 2
category: "Cardiac Surgery"
---

# Valvular Heart Surgery

## Overview

Valvular heart surgery encompasses procedures to repair or replace diseased cardiac valves. Valve pathology includes stenosis (narrowing), regurgitation (insufficiency), or mixed lesions affecting the mitral, aortic, tricuspid, or pulmonary valves. Surgical intervention aims to restore normal hemodynamics, relieve symptoms, prevent heart failure, and improve survival. Understanding valve pathophysiology, timing of intervention, surgical techniques, and prosthetic valve options is essential for optimal patient management.

## Valve Pathophysiology

### Aortic Valve Disease

**Aortic Stenosis (AS)**
- **Etiology**:
  - Degenerative calcific (most common, elderly)
  - Bicuspid aortic valve (congenital, presents earlier)
  - Rheumatic heart disease (less common in developed countries)
- **Pathophysiology**: Valve calcification → reduced orifice area → left ventricular outflow obstruction → LV hypertrophy
- **Hemodynamics**:
  - Normal valve area: 3-4 cm²
  - Mild AS: 1.5-2.0 cm²
  - Moderate AS: 1.0-1.5 cm²
  - Severe AS: <1.0 cm²
  - Critical AS: <0.75 cm²

**Aortic Regurgitation (AR)**
- **Etiology**:
  - Aortic root dilatation (aneurysm, Marfan syndrome)
  - Degenerative valve disease
  - Endocarditis
  - Bicuspid valve
  - Rheumatic disease
- **Pathophysiology**: Incompetent valve → blood regurgitates into LV during diastole → volume overload → LV dilatation
- **Hemodynamics**: Regurgitant volume, regurgitant fraction, effective regurgitant orifice area

### Mitral Valve Disease

**Mitral Stenosis (MS)**
- **Etiology**: Rheumatic heart disease (>90% of cases)
- **Pathophysiology**: Commissural fusion, leaflet thickening → reduced valve orifice → LA pressure elevation → pulmonary hypertension
- **Hemodynamics**:
  - Normal valve area: 4-6 cm²
  - Mild MS: >1.5 cm²
  - Moderate MS: 1.0-1.5 cm²
  - Severe MS: <1.0 cm²

**Mitral Regurgitation (MR)**
- **Etiology**:
  - **Primary (organic)**: Myxomatous degeneration (mitral valve prolapse), rheumatic disease, endocarditis, chordal rupture
  - **Secondary (functional)**: LV dilatation, ischemic papillary muscle dysfunction
- **Pathophysiology**: Incompetent valve → blood regurgitates into LA during systole → LA and LV volume overload
- **Carpentier Classification**:
  - Type I: Normal leaflet motion (annular dilatation, perforation)
  - Type II: Excessive leaflet motion (prolapse, chordal rupture, elongation)
  - Type IIIa: Restricted leaflet motion (diastolic, rheumatic)
  - Type IIIb: Restricted leaflet motion (systolic, ischemic)

### Tricuspid and Pulmonary Valve Disease

**Tricuspid Regurgitation (TR)**
- **Primary**: Endocarditis, rheumatic disease, carcinoid, congenital (Ebstein anomaly)
- **Secondary (functional)**: RV dilatation, pulmonary hypertension (most common)

**Pulmonary Valve Disease**
- Uncommon in adults
- Congenital (pulmonary stenosis, regurgitation)

## Indications for Valve Surgery

### Aortic Stenosis

**Class I Indications** (ACC/AHA Guidelines)
- **Symptomatic severe AS**: Angina, syncope, dyspnea, heart failure
- **Asymptomatic severe AS** with:
  - LVEF <50%
  - Undergoing other cardiac surgery (CABG, aorta, other valve)
  - Abnormal exercise test (symptoms, hypotension)
- **Very severe AS**: Aortic velocity >5 m/s, mean gradient >60 mmHg

**Class IIa Indications**
- Asymptomatic severe AS with rapid progression (velocity increase >0.3 m/s/year)
- Asymptomatic severe AS with elevated BNP (>3× normal)
- Moderate AS undergoing other cardiac surgery

### Aortic Regurgitation

**Class I Indications**
- **Symptomatic severe AR**: Dyspnea, angina, heart failure
- **Asymptomatic severe AR** with:
  - LVEF <50%
  - LV end-systolic dimension (LVESD) >50 mm or indexed LVESD >25 mm/m²
  - LV end-diastolic dimension (LVEDD) >65 mm
  - Undergoing other cardiac surgery

**Class IIa Indications**
- Asymptomatic severe AR with progressive LV dilatation (LVEDD >65 mm) or declining exercise tolerance

### Mitral Stenosis

**Class I Indications**
- **Symptomatic severe MS** (valve area <1.5 cm²)
- **Asymptomatic severe MS** with pulmonary hypertension (PASP >50 mmHg)

**Percutaneous Mitral Balloon Valvuloplasty (PMBV) Preferred**
- Favorable valve anatomy (pliable, non-calcified, minimal regurgitation)
- Surgery for: Unfavorable anatomy, severe MR, LA thrombus

### Mitral Regurgitation

**Class I Indications**
- **Symptomatic severe primary MR**: NYHA II-IV
- **Asymptomatic severe primary MR** with:
  - LVEF 30-60%
  - LV end-systolic dimension ≥40 mm
  - New-onset atrial fibrillation
  - Pulmonary hypertension (PASP >50 mmHg)
- **Secondary severe MR**: Undergoing CABG

**Class IIa Indications**
- Asymptomatic severe primary MR with preserved LV function if high likelihood of repair with low surgical risk

## Aortic Valve Replacement (AVR)

### Surgical Aortic Valve Replacement (SAVR)

**Preoperative Assessment**
- Echocardiography: Valve anatomy, severity, LV function, other valves
- Cardiac catheterization: Coronary anatomy, hemodynamics
- CT chest: Aortic dimensions, calcification, porcelain aorta
- Risk stratification: STS score, EuroSCORE

**Operative Technique**
1. **Median sternotomy**: Standard approach
2. **Cardiopulmonary bypass**: Aortic and right atrial cannulation
3. **Cardioplegia**: Cardiac arrest, myocardial protection
4. **Aortotomy**: Transverse or oblique incision in ascending aorta above sinotubular junction
5. **Valve excision**:
   - Remove calcified leaflets
   - Extensive debridement of calcium from annulus (avoid AV node injury, coronary ostia)
   - Rinse field (prevent calcium embolization)
6. **Annulus sizing**: Measure with valve sizers
7. **Suture placement**:
   - Interrupted pledgeted mattress sutures
   - Supra-annular (above annulus) or intra-annular placement
8. **Prosthesis implantation**: Lower valve into position, tie sutures
9. **Closure**: Close aortotomy, de-air left ventricle and aorta
10. **Wean CPB**: Assess valve function with TEE
11. **Hemostasis and closure**

**Valve Types and Selection**
- **Mechanical valves**: Durability, lifelong anticoagulation required
- **Bioprosthetic valves**: No long-term anticoagulation (except first 3-6 months), limited durability
- Choice depends on: Age, anticoagulation risk/contraindication, patient preference

### Transcatheter Aortic Valve Replacement (TAVR)

**Indications**
- **Class I**: Severe symptomatic AS in patients:
  - Prohibitive surgical risk (STS >8%, or frailty, porcelain aorta, severe comorbidities)
  - High surgical risk (STS 4-8%)
- **Class IIa**: Intermediate surgical risk (STS <4%)
- **Expanding indications**: Low surgical risk (PARTNER 3, Evolut Low Risk trials)

**Contraindications**
- Inadequate vascular access
- Bicuspid valve (relative, improving outcomes with newer devices)
- Annulus size outside device range
- Endocarditis
- Severe AR (primary indication)

**Approach**
- **Transfemoral** (most common, least invasive): Percutaneous femoral artery access
- **Transapical**: Left thoracotomy, LV apex puncture
- **Transaortic**: Upper sternotomy, direct aortic access
- **Transsubclavian/axillary**: Alternative arterial access

**Valve Types**
- **Balloon-expandable**: Edwards SAPIEN (requires pre-dilatation)
- **Self-expanding**: Medtronic CoreValve, Evolut (supra-annular, better for small annulus)

**Procedure Steps**
1. **Access**: Usually transfemoral via percutaneous technique
2. **Pre-dilatation**: Balloon valvuloplasty (for balloon-expandable valves)
3. **Valve positioning**: Position across annulus under fluoroscopy/TEE guidance
4. **Deployment**: Balloon inflation (balloon-expandable) or self-expansion
5. **Post-dilatation**: If paravalvular leak or underexpansion
6. **Closure**: Percutaneous closure device for arterial access

**Complications**
- **Vascular complications** (5-15%): Dissection, perforation, bleeding, need for surgical repair
- **Paravalvular leak (PVL)**: Mild common, moderate-severe (5-10%) associated with increased mortality
- **Stroke** (2-4%): Embolic from calcium, thrombus, air
- **AV block/pacing** (10-30%, higher with self-expanding valves): Damage to conduction system
- **Coronary obstruction** (<1%): Leaflet occluding coronary ostia
- **Annular rupture** (<1%): Catastrophic, high mortality
- **Valve migration, embolization** (rare)

**Outcomes**
- **PARTNER 3 Trial** (Low Risk): TAVR non-inferior to SAVR at 1 year (mortality/stroke/rehospitalization)
- **Evolut Low Risk Trial**: TAVR superior to SAVR at 2 years (mortality/stroke)
- Faster recovery, shorter hospital stay vs. SAVR
- Long-term durability data emerging (10-year data showing good durability)

### Aortic Valve Repair

**Indications**
- Aortic regurgitation due to:
  - Aortic root dilatation (valve-sparing root replacement)
  - Prolapsing cusp
  - Perforation
- Not for calcific AS

**Techniques**
- **Cusp repair**: Plication, pericardial patch
- **Valve-sparing root replacement**:
  - **David procedure**: Reimplantation of valve into Dacron graft
  - **Yacoub procedure**: Remodeling of root with Dacron graft
- Advantage: Avoid prosthetic valve and anticoagulation
- Disadvantage: Technical complexity, risk of repair failure

## Mitral Valve Surgery

### Mitral Valve Repair

**Advantages of Repair vs. Replacement**
- Preserve native valve and subvalvular apparatus
- Better LV function preservation
- Lower operative mortality
- Lower thromboembolic risk (no anticoagulation long-term)
- Lower endocarditis risk
- Preferred for primary MR when feasible

**Techniques for Mitral Regurgitation**

**Annuloplasty**
- **Rigid or semi-rigid ring**: Reduces annular size, restores leaflet coaptation
- **Flexible band**: Less remodeling
- Standard for virtually all MR repairs

**Leaflet Repair**
- **Triangular or quadrangular resection**: Remove prolapsing segment (posterior leaflet)
- **Chordal transfer**: Transfer chords from posterior to anterior leaflet
- **Chordal shortening**: Shorten elongated chords
- **Artificial chords (neochords)**: ePTFE sutures from papillary muscle to leaflet
- **Edge-to-edge repair (Alfieri stitch)**: Suture anterior and posterior leaflet edges together (for central regurgitation)

**Chordal Procedures**
- **Chordal transposition**: Move chords from posterior to anterior leaflet
- **Chordal replacement**: Artificial ePTFE chords

**Operative Approach**
1. **Median sternotomy** (standard) or **right mini-thoracotomy** (minimally invasive)
2. **CPB, cardioplegia**
3. **LA incision**: Expose mitral valve (interatrial groove, transseptal, or dome of LA)
4. **Valve assessment**: Identify pathology (prolapse, chordal rupture, leaflet perforation)
5. **Repair technique**: Combination of annuloplasty, leaflet repair, chordal procedures
6. **Saline test**: Inject saline into LV to assess competence
7. **TEE assessment**: Post-repair evaluation (residual MR)

**Outcomes**
- Repair success: 90-95% for myxomatous disease (degenerative)
- Lower success for: Rheumatic disease, endocarditis, ischemic/functional MR
- Durability: >90% freedom from reoperation at 10 years (degenerative MR)

### Mitral Valve Replacement (MVR)

**Indications**
- Unrepairable mitral valve
- Extensive leaflet destruction (endocarditis)
- Severe calcification
- Rheumatic disease with fibrosis
- Failed prior repair

**Operative Technique**
1. **Median sternotomy, CPB**
2. **LA incision**: Expose valve
3. **Valve excision**:
   - Remove anterior and posterior leaflets
   - **Chordal preservation** (when possible): Preserve subvalvular apparatus to maintain LV geometry and function
4. **Annulus sizing**
5. **Prosthesis implantation**:
   - Interrupted or continuous sutures
   - Supra-annular (on atrial side) or intra-annular placement
6. **Closure, de-airing**
7. **TEE assessment**

**Chordal Preservation Techniques**
- Preserve posterior leaflet and chordae entirely
- Preserve portions of anterior leaflet chordae
- Benefit: Improved LV function, survival

**Prosthesis Selection**
- **Mechanical**: Young patients (<60 years), able to take anticoagulation
- **Bioprosthetic**: Elderly (>65 years), anticoagulation contraindication, patient preference
- Lower threshold for bioprosthetic in mitral position vs. aortic (higher gradient with mechanical mitral valves)

### Transcatheter Mitral Valve Interventions

**MitraClip (Transcatheter Edge-to-Edge Repair)**
- **Indication**:
  - Severe symptomatic primary MR with prohibitive/high surgical risk
  - Moderate-to-severe secondary (functional) MR despite optimal medical therapy
- **Technique**: Percutaneous transseptal approach, clip anterior and posterior leaflets (Alfieri technique)
- **Outcomes**:
  - **COAPT Trial** (secondary MR): Reduced hospitalization and mortality vs. medical therapy
  - **EVEREST II Trial** (primary MR): Less effective than surgery but safer in high-risk patients
- Reduces MR to mild or less in ~70% of patients

**Transcatheter Mitral Valve Replacement (TMVR)**
- Emerging technology
- **Indications**: Failed prior surgical valve (valve-in-valve), failed annuloplasty ring (valve-in-ring)
- **Native TMVR**: Investigational

## Ross Procedure (Pulmonary Autograft)

### Concept

- Replace diseased aortic valve with patient's own pulmonary valve (autograft)
- Replace pulmonary valve with homograft (cadaveric donor valve)
- **Advantage**: Living autograft grows with patient, no anticoagulation
- **Disadvantage**: Complex surgery, two valves involved, potential for reoperation

### Indications

- **Young patients** (<50 years, especially <40 years) with aortic valve disease
- Active patients desiring no anticoagulation
- Women desiring pregnancy (no warfarin)
- Contraindication to anticoagulation
- Endocarditis

### Contraindications

- Significant aortic root dilatation (>4.5 cm)
- Connective tissue disorder (Marfan, Loeys-Dietz)
- Bicuspid valve with aortopathy
- Rheumatic disease (may affect pulmonary valve)

### Operative Technique

1. **Median sternotomy, CPB**
2. **Harvest pulmonary autograft**:
   - Excise pulmonary valve with rim of RV and main PA
   - Includes coronary buttons
3. **Excise aortic valve and root**
4. **Implant pulmonary autograft**:
   - **Root replacement** (most common): Replace entire aortic root
   - **Subcoronary**: Implant within native aortic root
   - Reimplant coronary arteries into autograft
5. **Pulmonary valve replacement**: Homograft (cadaveric pulmonary or aortic valve) in pulmonary position
6. **Closure, de-airing, wean CPB**

### Outcomes

- **Excellent hemodynamics**: No prosthesis-patient mismatch
- **Low thromboembolicity**: No anticoagulation needed
- **Durability**: >80% freedom from autograft reoperation at 20 years
- **Pulmonary homograft**: 30-50% require replacement by 15-20 years (well-tolerated, low pressure system)
- **Operative mortality**: 2-5% (complex procedure)
- **Complications**: Autograft dilatation (10-20% at 10 years), autograft regurgitation, homograft degeneration

## Tricuspid Valve Surgery

### Indications

**Class I**
- Severe TR undergoing left-sided valve surgery
- Symptomatic severe primary TR

**Class IIa**
- Progressive TR with annular dilatation (≥40 mm or >21 mm/m²) undergoing left-sided valve surgery

### Repair Techniques

**Annuloplasty**
- Most common: Ring or band annuloplasty
- **De Vega**: Purse-string suture along annulus (no ring)
- **Kay**: Bicuspidization (exclude posterior leaflet)

**Outcomes**
- Repair preferred over replacement
- Moderate residual TR common but well-tolerated
- Recurrent TR risk: ~20-30% at 5 years

### Replacement
- For unrepairable valves: Severe leaflet destruction (endocarditis, carcinoid, Ebstein anomaly)
- Bioprosthetic valve preferred (less thromboembolic risk than mechanical)

## Prosthetic Valves

### Mechanical Valves

**Types**
- **Bileaflet** (most common): St. Jude, On-X, ATS
- **Tilting disc** (less common): Medtronic Hall
- **Ball and cage** (obsolete): Starr-Edwards

**Advantages**
- **Durability**: Excellent long-term structural integrity
- **Longevity**: Essentially lifelong

**Disadvantages**
- **Anticoagulation**: Lifelong warfarin required
  - INR 2.5-3.5 (mitral, tricuspid)
  - INR 2.0-3.0 (aortic)
  - Bleeding risk, warfarin interactions, monitoring
- **Thromboembolism**: 1-2% per year despite anticoagulation
- **Valve thrombosis**: Rare but life-threatening
- **Hemolysis**: Mild, usually clinically insignificant
- **Audible click**: Psychologically bothersome to some patients

**Indications**
- Age <50-60 years (controversial cutoff)
- Already on anticoagulation (atrial fibrillation, prior thromboembolism)
- Renal failure (bioprosthetic valves degenerate faster)
- Patient preference (informed decision)

### Bioprosthetic Valves

**Types**
- **Stented porcine**: Medtronic Mosaic, Carpentier-Edwards
- **Stented bovine pericardial**: Carpentier-Edwards Perimount, St. Jude Trifecta
- **Stentless**: Medtronic Freestyle, St. Jude Toronto SPV (better hemodynamics)

**Advantages**
- **No long-term anticoagulation**: Aspirin only (warfarin × 3-6 months if sinus rhythm)
- **Low thromboembolism**: 0.5-1% per year without anticoagulation
- **Silent operation**

**Disadvantages**
- **Limited durability**: Structural valve deterioration (SVD)
  - 10-year freedom from SVD: ~80-90%
  - 15-year freedom from SVD: ~60-70%
  - 20-year freedom from SVD: ~40-50%
- **Faster degeneration** in: Younger patients, renal failure, hyperparathyroidism, pregnancy
- **Reoperation risk**: 1-3% per year after 10 years

**Indications**
- Age >65 years (aortic), >70 years (mitral)
- Anticoagulation contraindication or high bleeding risk
- Patient preference (avoid warfarin)
- Women desiring pregnancy

**Newer Bioprosthetic Technologies**
- Anti-calcification treatments (reduce SVD)
- Intermediate-term data showing improved durability

### Homografts (Allografts)

- Cadaveric human valves (cryopreserved)
- **Indications**: Aortic valve endocarditis (resistance to reinfection), complex aortic root disease
- **Advantages**: Excellent hemodynamics, low thromboembolicity, no anticoagulation
- **Disadvantages**: Limited availability, degeneration (similar to bioprosthetic), difficult reoperation

## Postoperative Management

### Immediate Postoperative (ICU)

**Hemodynamic Monitoring**
- Arterial line, CVP, PA catheter (if needed)
- TEE: Assess valve function, ventricular function, rule out tamponade

**Anticoagulation**
- **Mechanical valves**: Heparin bridge to warfarin
  - Start warfarin POD #1
  - Heparin infusion (therapeutic aPTT) until INR therapeutic
  - Target INR achieved (usually POD #3-5)
- **Bioprosthetic valves**: Heparin/warfarin × 3 months (if sinus rhythm), then aspirin

**Arrhythmia Management**
- Atrial fibrillation (30-40%): Beta-blockers, amiodarone
- Maintain sinus rhythm when possible
- Temporary pacing wires for AV block (especially post-AVR, TAVR)

**Ventilation, Pain, Early Mobilization**
- Similar to CABG management

### Intermediate and Long-Term

**Anticoagulation Monitoring**
- Mechanical valves: Lifelong warfarin, INR checks
- Bioprosthetic valves: Warfarin × 3 months → aspirin

**Endocarditis Prophylaxis**
- For all prosthetic valves
- High-risk dental, GI, GU procedures: Amoxicillin 2 g PO 1 hour pre-procedure

**Follow-Up**
- Echocardiography: Baseline (pre-discharge), 6-12 months, then annually or if symptoms
- Assess: Valve function, gradients, regurgitation, ventricular function

**Activity**
- Sternal precautions × 6-8 weeks
- Cardiac rehabilitation
- Gradual return to normal activity

## Complications

### Intraoperative

**Bleeding**
- Extensive calcification removal
- Annular disruption, ventricular rupture (rare, catastrophic)
- Management: Pledgeted sutures, patch repair

**Heart Block**
- AVR: Proximity to AV node (3-5% permanent pacemaker)
- TAVR: 10-30% permanent pacemaker (especially self-expanding valves)

**Coronary Obstruction**
- AVR/TAVR: Leaflet occluding coronary ostia (<1%)
- Management: Immediate revascularization

### Early Postoperative

**Prosthetic Valve Dysfunction**
- **Paravalvular leak**: Perivalvular regurgitation due to dehiscence
  - Mild: Common, usually benign
  - Moderate-severe: Hemolysis, heart failure, consider reoperation
- **Valve thrombosis**: Acute presentation with valve dysfunction, heart failure, shock
  - Diagnosis: TEE, fluoroscopy (restricted leaflet motion)
  - Management: Thrombolysis vs. emergent reoperation

**Stroke**
- Embolic (air, thrombus, calcium): 1-3% (SAVR), 2-4% (TAVR)

**Bleeding**
- Anticoagulation for mechanical valves
- Re-exploration if excessive

**Endocarditis**
- Early (<1 year): 1-3%
- Typically S. aureus, S. epidermidis
- High mortality (30-40%)

### Late Complications

**Structural Valve Deterioration (SVD)**
- Bioprosthetic valves: Leaflet calcification, tear, perforation
- Presentation: Recurrent stenosis and/or regurgitation
- Management: Redo valve replacement (surgical or valve-in-valve TAVR/TMVR)

**Prosthetic Valve Endocarditis (PVE)**
- Incidence: 0.3-1.2% per patient-year
- **Early PVE** (<1 year): S. aureus, S. epidermidis, gram-negative
- **Late PVE** (>1 year): Streptococcus, enterococcus
- **Management**: Prolonged IV antibiotics (4-6 weeks), surgery if complications (abscess, dehiscence, heart failure, persistent infection)

**Thromboembolism**
- Mechanical valves: 1-2% per year despite anticoagulation
- Stroke, TIA, peripheral embolism

**Anticoagulation-Related Bleeding**
- Mechanical valves on warfarin: Major bleeding 1-2% per year

**Hemolysis**
- Mechanical valves: Mild, usually subclinical
- Paravalvular leak: Can cause significant hemolysis

**Valve Thrombosis**
- Mechanical valves: 0.1-0.5% per patient-year
- Inadequate anticoagulation, low-flow states

**Pannus Formation**
- Fibrous tissue overgrowth obstructing mechanical valve
- Rare, more common in mitral position

## Outcomes

### Operative Mortality

- **Isolated AVR**: 1-3%
- **Isolated MVR**: 3-6%
- **TAVR**: 1-3% (30-day mortality)
- **Combined valve + CABG**: 4-8%
- Higher risk: Urgency, elderly, low EF, renal dysfunction, redo surgery

### Long-Term Survival

**Aortic Valve Replacement**
- 5-year survival: 75-85%
- 10-year survival: 55-70%
- Improved survival vs. untreated severe AS

**Mitral Valve Repair**
- 5-year survival: 85-95%
- 10-year survival: 70-80%
- Excellent outcomes for degenerative MR

**Mitral Valve Replacement**
- 5-year survival: 65-75%
- 10-year survival: 50-60%
- Lower than repair (reflects patient selection, loss of native valve)

### Functional Outcomes

- Significant symptom improvement in >80% of patients
- NYHA class I-II: 70-80% at 5 years
- Improved exercise tolerance, quality of life

### Prosthesis Durability

**Mechanical Valves**
- Excellent long-term structural integrity
- >95% free from structural failure at 20 years

**Bioprosthetic Valves**
- Freedom from SVD: 80-90% at 10 years, 60-70% at 15 years
- Younger patients have faster degeneration

## Key Points

1. **Aortic stenosis** becomes symptomatic with angina, syncope, or dyspnea; symptomatic severe AS has poor prognosis without intervention (2-year survival ~50%).

2. **TAVR** has expanded indications from prohibitive/high-risk to low-risk patients; PARTNER 3 and Evolut Low Risk trials showed non-inferiority or superiority vs. SAVR.

3. **Mitral valve repair** is preferred over replacement for primary MR when feasible; provides better survival, LV function preservation, and avoids long-term anticoagulation.

4. **Mechanical valves** require lifelong anticoagulation (warfarin, target INR 2.0-3.0 aortic, 2.5-3.5 mitral) but offer excellent durability; preferred in younger patients (<60 years).

5. **Bioprosthetic valves** avoid long-term anticoagulation but have limited durability (10-year freedom from SVD ~80-90%); preferred in elderly (>65 years).

6. **Ross procedure** (pulmonary autograft) is the operation of choice for young patients (<40 years) with aortic valve disease, offering a living valve without anticoagulation.

7. **Paravalvular leak** after TAVR occurs in 5-10% (moderate-severe); associated with increased mortality; addressed with post-dilatation or second valve.

8. **Permanent pacemaker** is required in 10-30% of TAVR patients (higher with self-expanding valves) due to conduction system injury.

9. **Prosthetic valve endocarditis** (PVE) occurs at 0.3-1.2% per patient-year; early PVE (<1 year) is typically S. aureus; late PVE (>1 year) is streptococcus.

10. **Structural valve deterioration** (SVD) of bioprosthetic valves can be treated with valve-in-valve TAVR/TMVR, avoiding redo sternotomy in high-risk patients.

## References

1. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2017;135(25):e1159-e1195.

2. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. (PARTNER 3)

3. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1706-1715. (Evolut Low Risk)

4. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379(24):2307-2318. (COAPT)

5. David TE, Armstrong S, Ivanov J, et al. Results of aortic valve-sparing operations. J Thorac Cardiovasc Surg. 2001;122(1):39-46.

6. Svensson LG, Blackstone EH, Alsalihi M, et al. Midterm results of the Ross procedure: a report from the Cleveland Clinic. J Thorac Cardiovasc Surg. 2000;120(4):752-758.

7. Carpentier A, Deloche A, Dauptain J, et al. A new reconstructive operation for correction of mitral and tricuspid insufficiency. J Thorac Cardiovasc Surg. 1971;61(1):1-13.

8. Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2009;87(5):1431-1437.

9. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395-1406. (EVEREST II)

10. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376(14):1321-1331. (SURTAVI)
